<DOC>
	<DOCNO>NCT01467999</DOCNO>
	<brief_summary>The purpose study determine whether guanfacine represent tolerable , potentially effective pharmacotherapy option cannabis dependence . Interested see whether guanfacine treatment reduces marijuana consumption , withdrawal symptom , crave compare baseline .</brief_summary>
	<brief_title>Open-Label Pilot Study Guanfacine-Extended Release Treatment Cannabis Dependence</brief_title>
	<detailed_description>Cannabis use disorder remain common illicit drug use disorder option treatment remain limited . Compared abusable substance , little investigation pharmacotherapies cannabis dependence effective pharmacotherapy cannabis dependence develop yet . As , development effective cannabis dependence pharmacotherapy important unmet public health need . Lofexidine , alpha-2 agonist , effective treat opioid withdrawal show promise cannabis use disorder pharmacotherapy , though use may limit cumbersome ( thrice daily ) dose regimen . An alpha-2-agonist long half-life , guanfacine , may benefit lofexidine comparable dos , easy ( daily ) dose regimen may promote compliance treatment retention . The purpose study therefore determine whether guanfacine represent tolerable , potentially effective pharmacotherapy option cannabis dependence . This pilot study also provide basis subsequently conduct large study aim determine efficacy appropriate randomize , placebo-controlled design .</detailed_description>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>Men woman age 1860 meet DSMIV criterion current marijuana dependence Individuals must report use marijuana least 20 day past 30 day positive urine test THC day study entry . Individual must describe marijuana primary drug abuse . Individuals must capable give informed consent capable comply study procedure . Meets DSMIVTR criterion schizophrenia , schizoaffective illness , psychotic disorder transient psychosis due drug abuse , major depression , bipolar illness psychiatric disorder ( substance abuse ) require psychiatric intervention . Unstable medication condition , poorly control diabetes hypertension ( &gt; 140/90 mmHg ) , might make participation hazardous . Individuals liver enzyme function test great three time normal , acute hepatitis Individuals history seizure disorder Individuals current suicidal risk . Individuals cognitively impaired Bradycardia ( &lt; 50 beats/minute ) , hypotension ( sit stand BP &lt; 90/50 ) , symptom attributable low BP ( i.e . lightheadedness dizziness stand ) . Nursing mother pregnant woman . Women child bear age include study provide pregnant , base result blood pregnancy test drawn time screen . They must also agree use method contraception proven efficacy agree become pregnant study . To confirm , urine pregnancy test repeat monthly . Women provide full explanation potential danger pregnancy study medication . If woman become pregnant , study medication discontinue . Individuals physiologically dependent drug ( exclude nicotine ) would require medical intervention Individuals know sensitivity alpha2 Agonists Individuals coronary vascular disease indicate history suspect abnormal ECG history cardiac symptom Individuals currently treat antihypertensive medication , include alpha2 agonist Individuals currently take medication may interact adversely guanfacine . Individuals courtmandated treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>cannabis dependence</keyword>
	<keyword>marijuana dependence</keyword>
	<keyword>guanfacine</keyword>
</DOC>